Evaxion Biotech A/S ADR (EVAX)

$1.66 +0.02 (1.22%)
Market Cap 2.30M
Revenue (ttm) 3.34M
Net Income (ttm) -10.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -316.47%
Debt to Equity Ratio -4.95
Volume 57,600
Avg Vol 68,002
Day's Range N/A - N/A
Shares Out 1.40M
Stochastic %K 76%
Beta -0.24
Analysts Strong Sell
Price Target $13.25

Company Profile

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 31 31 97 53
Website: evaxion.ai
Address:
Dr. Neergaards Vej, 5th Floor, Horsholm, Denmark
Olsen71
Olsen71 Oct. 24 at 1:57 PM
$EVAX 6-7-8-9...... 20 🚀💪
0 · Reply
NoNoNoNoNoNoYesNo
NoNoNoNoNoNoYesNo Oct. 23 at 2:24 PM
$EVAX average at 9. Not buying more as it's already heavy bag. That being said, I can see it rocketing back up to 12 range in days based on recent price activity and updates on their products.
0 · Reply
veseli
veseli Oct. 23 at 11:23 AM
$EVAX
0 · Reply
Peaceouty
Peaceouty Oct. 22 at 8:15 PM
$EVAX missed chance. Too tight on the budget. Not enough p2 patients.
0 · Reply
Olsen71
Olsen71 Oct. 22 at 6:17 PM
$EVAX
0 · Reply
Manwiththeplan
Manwiththeplan Oct. 22 at 5:04 PM
$EVAX the dilution was unexpected. I guess it tells a deal is not around the corner. I learned from the webcast they are likely discussing EVX01 with potential partners. Now we have ppl selling in some panic. I think this can continue to a market cap of 30-40million.
3 · Reply
Manwiththeplan
Manwiththeplan Oct. 22 at 5:01 PM
$EVAX nice i am scooping up shares. Small bits.
1 · Reply
Olsen71
Olsen71 Oct. 22 at 3:44 PM
$EVAX Good webinar.. Exciting what such good results from your product can lead to 💪 Best results available right now in the treatment of melanoma, so I simply don't understand the low price right now, where the next few weeks can go and a price rocket 🚀 Well, just my opinion, we'll have to see what happens in the long run..
1 · Reply
Manwiththeplan
Manwiththeplan Oct. 22 at 3:17 PM
$EVAX nice discussions in the phase 2 data webinar
1 · Reply
NoNoNoNoNoNoYesNo
NoNoNoNoNoNoYesNo Oct. 22 at 2:44 PM
$EVAX F Cancer. If that doesn't get a Like, I don't know what will.
0 · Reply
Latest News on EVAX
Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript

Oct 22, 2025, 5:13 PM EDT - 3 days ago

Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Oct 17, 2025, 8:15 AM EDT - 8 days ago

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Oct 13, 2025, 8:00 AM EDT - 12 days ago

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Oct 8, 2025, 8:12 AM EDT - 17 days ago

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Oct 3, 2025, 9:00 AM EDT - 22 days ago

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Evaxion A/S - Special Call

Sep 25, 2025, 11:07 AM EDT - 4 weeks ago

Evaxion A/S - Special Call

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Sep 25, 2025, 7:00 AM EDT - 4 weeks ago

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 3:29 PM EDT - 2 months ago

Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Aug 11, 2025, 8:00 AM EDT - 2 months ago

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Jul 25, 2025, 9:00 AM EDT - 3 months ago

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Evaxion finalizes agreement with EIB to convert debt into equity

Jul 11, 2025, 8:00 AM EDT - 3 months ago

Evaxion finalizes agreement with EIB to convert debt into equity

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Jul 1, 2025, 8:30 AM EDT - 4 months ago

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Jun 25, 2025, 8:00 AM EDT - 4 months ago

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Evaxion receives grant funding to design new polio vaccine

Jun 3, 2025, 9:15 AM EDT - 5 months ago

Evaxion receives grant funding to design new polio vaccine

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript

May 27, 2025, 10:43 AM EDT - 5 months ago

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript

Evaxion announces business update and first quarter 2025 financial results

May 27, 2025, 7:30 AM EDT - 5 months ago

Evaxion announces business update and first quarter 2025 financial results

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

May 26, 2025, 8:47 AM EDT - 5 months ago

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

May 23, 2025, 8:00 AM EDT - 5 months ago

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

May 22, 2025, 8:00 AM EDT - 5 months ago

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Apr 28, 2025, 8:00 AM EDT - 6 months ago

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Evaxion to present at World Vaccine Congress

Apr 10, 2025, 8:00 AM EDT - 7 months ago

Evaxion to present at World Vaccine Congress

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

Apr 1, 2025, 11:21 AM EDT - 7 months ago

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Mar 27, 2025, 8:00 AM EDT - 7 months ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 7 months ago

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Feb 25, 2025, 8:00 AM EST - 8 months ago

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Evaxion announces closing of $10.8 million public offering

Jan 31, 2025, 4:05 PM EST - 9 months ago

Evaxion announces closing of $10.8 million public offering

Evaxion announces pricing of $10.8 million public offering

Jan 30, 2025, 8:00 AM EST - 9 months ago

Evaxion announces pricing of $10.8 million public offering

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Jan 28, 2025, 8:15 AM EST - 9 months ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Evaxion announces completion of ADS ratio change

Jan 14, 2025, 4:05 PM EST - 10 months ago

Evaxion announces completion of ADS ratio change

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Jan 10, 2025, 8:00 AM EST - 10 months ago

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Evaxion announces plan to implement ADS ratio change

Dec 30, 2024, 8:00 AM EST - 10 months ago

Evaxion announces plan to implement ADS ratio change

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Nov 12, 2024, 8:00 AM EST - 1 year ago

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Evaxion announces business update and third quarter 2024 financial results

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Evaxion announces business update and third quarter 2024 financial results

Evaxion to announce business update and third quarter 2024 financial results on October 31

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Evaxion to announce business update and third quarter 2024 financial results on October 31

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Oct 3, 2024, 8:00 AM EDT - 1 year ago

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Evaxion Biotech Partners With Merck To Expand Vaccine Development

Sep 26, 2024, 10:53 AM EDT - 1 year ago

Evaxion Biotech Partners With Merck To Expand Vaccine Development

MRK

Evaxion significantly expands vaccine development collaboration with MSD

Sep 26, 2024, 7:30 AM EDT - 1 year ago

Evaxion significantly expands vaccine development collaboration with MSD

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 11:43 AM EDT - 1 year ago

Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

Aug 12, 2024, 7:27 AM EDT - 1 year ago

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference

Jul 16, 2024, 7:30 AM EDT - 1 year ago

Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update

Jul 3, 2024, 8:05 AM EDT - 1 year ago

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

Jun 26, 2024, 7:30 AM EDT - 1 year ago

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal

Jun 17, 2024, 8:44 AM EDT - 1 year ago

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal

Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024

Evaxion Announces Business Update and First Quarter 2024 Financial Results

May 28, 2024, 8:21 AM EDT - 1 year ago

Evaxion Announces Business Update and First Quarter 2024 Financial Results

Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

May 23, 2024, 5:00 PM EDT - 1 year ago

Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

Olsen71
Olsen71 Oct. 24 at 1:57 PM
$EVAX 6-7-8-9...... 20 🚀💪
0 · Reply
NoNoNoNoNoNoYesNo
NoNoNoNoNoNoYesNo Oct. 23 at 2:24 PM
$EVAX average at 9. Not buying more as it's already heavy bag. That being said, I can see it rocketing back up to 12 range in days based on recent price activity and updates on their products.
0 · Reply
veseli
veseli Oct. 23 at 11:23 AM
$EVAX
0 · Reply
Peaceouty
Peaceouty Oct. 22 at 8:15 PM
$EVAX missed chance. Too tight on the budget. Not enough p2 patients.
0 · Reply
Olsen71
Olsen71 Oct. 22 at 6:17 PM
$EVAX
0 · Reply
Manwiththeplan
Manwiththeplan Oct. 22 at 5:04 PM
$EVAX the dilution was unexpected. I guess it tells a deal is not around the corner. I learned from the webcast they are likely discussing EVX01 with potential partners. Now we have ppl selling in some panic. I think this can continue to a market cap of 30-40million.
3 · Reply
Manwiththeplan
Manwiththeplan Oct. 22 at 5:01 PM
$EVAX nice i am scooping up shares. Small bits.
1 · Reply
Olsen71
Olsen71 Oct. 22 at 3:44 PM
$EVAX Good webinar.. Exciting what such good results from your product can lead to 💪 Best results available right now in the treatment of melanoma, so I simply don't understand the low price right now, where the next few weeks can go and a price rocket 🚀 Well, just my opinion, we'll have to see what happens in the long run..
1 · Reply
Manwiththeplan
Manwiththeplan Oct. 22 at 3:17 PM
$EVAX nice discussions in the phase 2 data webinar
1 · Reply
NoNoNoNoNoNoYesNo
NoNoNoNoNoNoYesNo Oct. 22 at 2:44 PM
$EVAX F Cancer. If that doesn't get a Like, I don't know what will.
0 · Reply
Sarahsanjose2
Sarahsanjose2 Oct. 22 at 2:39 PM
$EVAX
0 · Reply
baldaldo
baldaldo Oct. 22 at 12:55 PM
$EVAX Ugh.
0 · Reply
saunderswe
saunderswe Oct. 21 at 5:12 PM
$EVAX We invite you to attend our upcoming online webinar this Wednesday at 16:30 CEST / 10:30 AM EDT, where Professor Adnan Khattak will present and discuss the newly released two-year phase 2 clinical data from EVX-01, Evaxion’s AI-designed personalized cancer vaccine. Secure your spot by registering here: http://events.teams.microsoft.com/event/3a4a908e… https://x.com/evaxionbiotech/status/1980596126727155814?s=46&t=McwaX0VZVm9KX06Vzv6rcA
1 · Reply
Sarahsanjose2
Sarahsanjose2 Oct. 21 at 3:51 PM
$EVAX it does not move. Is it halted?
0 · Reply
NoNoNoNoNoNoYesNo
NoNoNoNoNoNoYesNo Oct. 21 at 2:16 PM
$EVAX 🤮
0 · Reply
anachartanalyst
anachartanalyst Oct. 20 at 8:11 PM
$EVAX https://anachart.com/wp-content/uploads/ana_temp/1760972525_soc-img.jpg
0 · Reply
Babyhuey
Babyhuey Oct. 20 at 3:09 PM
$EVAX Trying to guess where to enter here can be dangerous to your wealth, IMO. There are too many deals on the table and in the deck to play yet. Market cap and shares outstanding screaming waaaaaay undervalued at this price.
1 · Reply
JarvisFlow
JarvisFlow Oct. 20 at 1:16 PM
Lake Street has updated their rating for Evaxion ( $EVAX ) to Buy with a price target of 11.
0 · Reply
JarvisFlow
JarvisFlow Oct. 20 at 12:02 PM
HC Wainwright & Co. updates rating for Evaxion ( $EVAX ) to Buy, target set at 16.
0 · Reply
Manwiththeplan
Manwiththeplan Oct. 20 at 8:57 AM
$EVAX - pipeline is full with preclinical treatments - market cap 42 million - there are multiple talks about deals - enough cash for +- 2 year - till now they make all their milestones for this year - positive news about deals will send this upwards I sold 75% of my shares with a large profit. Now i am confident waiting for what is next. If this goes down more i ll buy more.
0 · Reply
AlwaysBeHumble
AlwaysBeHumble Oct. 19 at 11:30 PM
$IVDA $MSS $EVAX $EZGO VRME chart is looking to gap up tmr. This is a known runner, has shown before it can run to $5+. Same bullish setup, Plus news!
0 · Reply
Peaceouty
Peaceouty Oct. 19 at 7:16 PM
$EVAX Still under the radar.
0 · Reply